Both trials demonstrated twice daily oral doses of nerandomilast (9 mg and 18 mg) significantly reduced the decline in forced vital capacity (FVC) from baseline at week 52, compared to placebo (adjusted mean change from baseline in FVC: FIBRONEER-IPF, -138.6 mL with nerandomilast 9 mg, -114.7 mL with nerandomilast 18 mg, -183.5 mL with placebo
Its weight-management evidence comes largely from the SURMOUNT trial program published in The New England Journal of Medicine in 2022, with SURMOUNT-OSA extending the data to obstructive sleep apnea in 2024
Peptide signalling pathways and cellular communication mechanisms
Ozempic might make you feel sick, vomit, or have diarrhea
Peroxynitrite is a potent oxidant capable of attacking all biomolecules
This approach allows clinicians to personalize therapy based on individual metabolic pathways and genetic predispositions, maximizing weight loss and metabolic health outcomes without proportional price increases